625 related articles for article (PubMed ID: 21310658)
1. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
[TBL] [Abstract][Full Text] [Related]
3. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
[TBL] [Abstract][Full Text] [Related]
4. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
7. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
11. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
12. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract][Full Text] [Related]
13. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
[TBL] [Abstract][Full Text] [Related]
14. Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick JM; Stone S; Lenz L; Flake DD; Rajamani S; Moller H; Berney DM; Cohen T; Scardino PT
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1535. PubMed ID: 34423592
[TBL] [Abstract][Full Text] [Related]
15. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
16. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of a cell cycle progression score for men with prostate cancer.
Cuzick J
Recent Results Cancer Res; 2014; 202():133-40. PubMed ID: 24531787
[TBL] [Abstract][Full Text] [Related]
18. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
Cooperberg MR; Cowan JE; Lindquist KJ; Kobayashi Y; Simko JP; Bengtsson H; Singh K; Ngo V; Avila A; Newcomb LF; Tretriakova M; Lin DW; Stone S; Carroll PR; Paris PL
Eur Urol; 2021 Jan; 79(1):141-149. PubMed ID: 33148472
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Sommariva S; Tarricone R; Lazzeri M; Ricciardi W; Montorsi F
Eur Urol; 2016 Jan; 69(1):107-15. PubMed ID: 25481455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]